Pharmacoepidemiology I: A Review of Pharmacoepidemiologic Study Designs

Authors

  • Dr. Mahyar Etminan Pharm.D., M.Sc.(Epid.),

    Corresponding author
    1. Division of Clinical Epidemiology, Royal Victoria Hospital, and McGill Health Centre, Montreal, Quebec, Canada
    2. Center for Clinical Epidemiology and Evaluation, Vancouver Hospital, Vancouver, British Columbia, Canada
    Search for more papers by this author
  • Dr. Ali Samii M.D.

    1. Department of Neurology, Faculty of Medicine, University of Washington, Seattle, Washington
    Search for more papers by this author

Division of Clinical Epidemiology, Royal Victoria Hospital, R.43-687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1; e-mail: mahyar.etminan@mail.mcgill.ca.

Abstract

This article is the first of two parts on pharmacoepidemiology, a relatively new science that explores drug efficacy or toxicity using large observational study designs. The number of pharmacoepidemiologic studies published in medical journals has increased, as these studies have explored drug-related questions that at times cannot be answered in randomized clinical trials. Four pharmacoepidemiologic study designs will be discussed that explore the association between a specific pharmacologic agent and a disease of interest: cohort studies, case-control studies, case-crossover studies, and case-time-control studies.

Ancillary